Works cites documents for "Colorectal Cancer".
Colorectal Cancer _ ___________________________________________________________________________ Works Cited 1. National Cancer Institute. Colorectal Cancer Screening: Health Professional Version. Available at https://www.cancer.gov/types/ colorectal/hp/colorectal-screening-pdq. Last accessed March 7, 2022. 2. Imperiale TF, Wagner DR, Lin CY, Larkin GN, Rogge JD, Ransohoff DF. Results of screening colonoscopy among persons 40 to 49 years of age. N Engl J Med . 2002;346(23):1781-1785. 3. Fuchs CS, Giovannucci EL, Colditz GA, Hunter DJ, Speizer FE, Willett WC. A prospective study of family history and the risk of colorectal cancer. N Engl J Med . 1994;331(25):1669-1674. 4. Keum N, Giovannucci EL. Folic acid fortification and colorectal cancer risk. Am J Prev Med . 2014;46(3 Suppl 1):S65-S72. 5. Nielsen A, Munk C, Kjaer SK. Trends in incidence of anal cancer and high-grade anal intraepithelial neoplasia in Denmark, 1978– 2008. Int J Cancer . 2012;130(5):1168-1173. 6. World Health Organization, International Agency for Research on Cancer. Cancer Fact Sheets: Colorectal Cancer. Available at https:// gco.iarc.fr/today/fact-sheets-cancers. Last accessed March 7, 2022. 7. American Cancer Society. Key Statistics for Colorectal Cancer. Available at https://www.cancer.org/cancer/colon-rectal-cancer/about/ key-statistics.html. Last accessed March 7, 2022.
8. American Cancer Society. Cancer Facts and Figures, 2022 . Atlanta, GA: American Cancer Society; 2022. 9. Siegel R, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin . 2022;72(1):7-33.
10. Noone AM, Howlader N, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2015 . Bethesda, MD: National Cancer Institute; 2018. 11. Laiyemo AO, Doubeni C, Pinsky PF, et al. Race and colorectal cancer disparities: health-care utilization vs. different cancer susceptibilities. J Natl Cancer Inst . 2010;102(8):538-546. 12. Sutton, E, Bellini G, Lee D, Njoh L, Whelan RL. An Update on Young-Onset Colorectal Cancer: An NCDB Analysis. Available at http://meetings.ssat.com/abstracts/2016/Tu1812.cgi. Last accessed March 7, 2022. 13. American Cancer Society. Survival Rates for Colorectal Cancer. Available at https://www.cancer.org/cancer/colon-rectal-cancer/ detection-diagnosis-staging/survival-rates.html.rectal-cancer/detection-diagnosis-staging/survival-rates.html. Last accessed March 7, 2022. 14. National Cancer Institute. Colorectal Cancer Prevention: Health Professional Version. Available at https://www.cancer.gov/types/ colorectal/hp/colorectal-prevention-pdq. Last accessed March 7, 2022. 15. Fedirko V, Tramacere I, Bagnardi V, et al. Alcohol drinking and colorectal cancer risk: an overall and dose-response meta-analysis of published studies. Ann Oncol . 2011;22(9):1958-1972. 16. Cho E, Smith-Warner SA, Ritz J, et al. Alcohol intake and colorectal cancer: a pooled analysis of 8 cohort studies. Ann Intern Med . 2004;140(8):603-613. 17. Haggar FA, Boushey PP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg . 2009;22(4):191-197. 18. Zisman AL, Nickolov A, Brand RE, Gorchow A, Roy HK. Associations between the age at diagnosis and location of colorectal cancer and the use of alcohol and tobacco: implications for screening. Arch Intern Med . 2006;166(6):629-634. 19. Botteri E, Iodice S, Bagnardi V, Raimondi S, Lowenfels AB, Maisonneuve P. Smoking and colorectal cancer: a meta-analysis. JAMA . 2008;300(23):2765-2778. 20. Liang PS, Chen TY, Giovannucci E. Cigarette smoking and colorectal cancer incidence and mortality: systematic review and meta- analysis. Int J Cancer . 2009;124(10):2406-2415. 21. Ma Y, Yang Y, Wang F, et al. Obesity and risk of colorectal cancer: a systematic review of prospective studies. PLoS One . 2013;8(1):e53916. 22. Bianchini F, Kaaks R, Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol . 2002;3(9):565-574. 23. Jacobs ET, Ahnen DJ, Ashbeck EL, et al. Association between body mass index and colorectal neoplasia at follow-up colonoscopy: a pooling study. Am J Epidemiol . 2009;169(6):657-666. 24. Gibson TM, Park Y, Robien K, et al. Body mass index and risk of second obesity-associated cancers after colorectal cancer: a pooled analysis of prospective cohort studies. J Clin Oncol . 2014;32(35):4004-4011. 25. Morikawa T, Kuchiba A, Lochhead P, et al. Prospective analysis of body mass index, physical activity, and colorectal cancer risk associated with ß-catenin (CTNNB1) status. Cancer Res . 2013;73(5):1600-1610. 26. Wolin KY, Yan Y, Colditz GA, Lee IM. Physical activity and colon cancer prevention: a meta-analysis. Br J Cancer. 2009;100(4):611-616. 27. Kruk J, Aboul-Enein HY. Physical activity and cancer prevention: updating the evidence. The role of oxidative stress in carcinogenesis. Curr Cancer Ther Rev . 2007;3(2):81-95. 28. Aleksandrova K, Jenab M, Leitzmann M, et al. Physical activity, mediating factors and risk of colon cancer: insights into adiposity and circulating biomarkers from the EPIC Cohort. Int J Epidemiol . 2017;46(6):1823-1835. 29. Boyle T, Keegel T, Bull F, Heyworth J, Fritschi L. Physical activity and risks of proximal and distal colon cancers: a systematic review and meta-analysis. J Natl Cancer Inst . 2012;104(20):1548-1561.
___________________________________________________________________________ Colorectal Cancer 30. Rose DP, Boyar AP, Wynder EL. International comparisons of mortality rates for cancer of the breast, ovary, prostate, and colon, and per capita food consumption. Cancer . 1986;58(11):2363-2371. 31. Reddy BS. Dietary fat and its relationship to large bowel cancer. Cancer Res . 1981;41(9 Pt 2):3700-3705. 32. Potter JD, McMichael AJ. Diet and cancer of the colon and rectum: a case-control study. J Natl Cancer Inst . 1986;76(4):557-569. 33. Bingham SA. Diet and large bowel cancer. J R Soc Med . 1990;83(7):420-422. 34. Augustsson K, Skog K, Jägerstad M, Dickman PW, Steineck G. Dietary heterocyclic amines and cancer of the colon, rectum, bladder, and kidney: a population-based study. Lancet . 1999;353(9154):703-707. 35. Forman D. Meat and cancer: a relation in search of a mechanism. Lancet . 1999;353(9154):686-687. 36. Fuchs CS, Giovannucci EL, Colditz GA, et al. Dietary fiber and the risk of colorectal cancer and adenoma in women. N Engl J Med . 1999;340(3):169-176. 37. Kunzmann AT, Coleman HG, Huang WY, Cantwell MM, Kitahara CM, Berndt SI. Fruit and vegetable intakes and risk of colorectal cancer and incident and recurrent adenomas in the PLCO cancer screening trial. Int J Cancer . 2016;138(8):1851-1861. 38. Jacobs ET, Lanza E, Alberts DS, et al. Fiber, sex, and colorectal adenoma: results of a pooled analysis. Am J Clin Nutr . 2006;83(2):343- 349. 39. Koushik A, Hunter DJ, Spiegelman D, et al. Fruits, vegetables, and colon cancer risk in a pooled analysis of 14 cohort studies. J Natl Cancer Inst . 2007;99(19):1471-1483. 40. Je Y, Jeon JY, Giovannucci EL, Meyerhardt JA. Association between physical activity and mortality in colorectal cancer: a meta-analysis of prospective cohort studies. Int J Cancer . 2013;133(8):1905-1913. 41. Man J, Zhang T, Yin X, et al. Spatiotemporal trends of colorectal cancer mortality due to low physical activity and high body mass index from 1990 to 2019: a global, regional, and national analysis. Front Med (Lausanne) . 2022;10(8):800426. 42. Meyerhardt JA, Niedzwiecki D, Hollis D, et al. Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. JAMA . 2007;298(7):754-764. 43. Meyerhardt JA, Sato K, Niedzwiecki D, et al. Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Natl Cancer Inst . 2012;104(22):1702-1711. 44. McCullough ML, Gapstur SM, Shah R, Jacobs EJ, Campbell PT. Association between red and processed meat intake and mortality among colorectal cancer survivors. J Clin Oncol . 2013;31(22):2773-2782. 45. Song M, Nishihara R, Wang M, et al. Plasma 25-hydroxyvitamin D and colorectal cancer risk according to tumour immunity status. Gut . 2016;65(2):296-304. 46. Rigas B, Tsioulias GJ. The evolving role of nonsteroidal anti-inflammatory drugs in colon cancer prevention: a cause for optimism. J Pharmacol Exp Ther . 2015;353(1):2-8. 47. Manson JE, Bassuk SS. Vitamin D research and clinical practice: at a crossroads. JAMA . 2015;313(13):1311-1312. 48. Boghossian S, Hawash A. Chemoprevention in colorectal cancer––where we stand and what we have learned from twenty years’ experience. Surgeon . 2012;10(1):43-52. 49. Benamouzig R, Uzzan B. Identification and chemoprevention in subjects at moderate risk of colorectal cancer. Best Pract Res Clin Gastroenterol . 2011;25(4-5):631-640. 50. Ng K, Meyerhardt JA, Chan AT, et al. Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. J Natl Cancer Inst . 2015;107(1):345. 51. Knights KM, Mangoni AA, Miners JO. Defining the COX inhibitor selectivity of NSAIDs: implications for understanding toxicity. Expert Rev Clin Pharmacol . 2010;3(6):769-776. 52. Chan AT, Arber N, Burn J, et al. Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev Res (Phila) . 2012;5(2):164-178. 53. Flossman E, Rothwell M. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomized and observational studies. Lancet . 2007;369(9573):1603-1613. 54. Burn J, Bishop DT, Mecklin JP, et al. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med . 2008;359(24):2567-2578. 55. Burn J, Gerdes AM, Macrae F, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet . 2011;378(9809):2081-2087. 56. Burn J, Sheth H, Elliott F, et al. Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. Lancet . 2020;395(10240):1855-1863. 57. Cooper K, Squires H, Carroll C, et al. Chemoprevention of colorectal cancer: systematic review and economic evaluation. Health Technol Assess . 2010;14(32):1-206. 58. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA . 2009;302(6):649-658. 59. Liao C, Gao F, Cao Y, Tan A, Li X, Wu D. Meta-analysis of the colon J-pouch vs. transverse coloplasty pouch after anterior resection for rectal cancer. Colorectal Dis . 2009;12(7):624-631.
Colorectal Cancer _ ___________________________________________________________________________ 60. U.S. Preventive Services Task Force. Final Recommendation Statement: Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Preventive Medication. Available at https://www.uspreventiveservicestaskforce.org/Page/Document/ RecommendationStatementFinal/aspirin-to-prevent-cardiovascular-disease-and-cancer. Last accessed March 7, 2022. 61. Rostom A, Dubé C, Lewin G, et al. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med . 2007;146(5):376-389. 62. Thun MJ, Blackard B. Pharmacologic effects of NSAIDs and implications for the risks and benefits of long-term prophylactic use of aspirin to prevent cancer. Recent Results Cancer Res . 2009;181:215-221. 63. Garcia-Albeniz X, Chan AT. Aspirin for the prevention of colorectal cancer. Best Pract Res Clin Gastroenterol . 2011;25(4-5): 461-472. 64. Federal Register. Pfizer, Inc. Withdrawal of Approval of Familial Adenomatous Polyposis Indication for CELEBREX. Available at https://www.federalregister.gov/articles/2012/06/08/2012-13900/pfizer-inc-withdrawal-of-approval-of-familial-adenomatous- polyposis-indication-for-celebrex. Last accessed March 7, 2022. 65. BlueCross BlueShield of North Carolina. COX-2 Inhibitors Utilization Management Criteria. Available at https://www.bluecrossnc. com/sites/default/files/document/attachment/services/public/pdfs/formulary/Cox-2-V485.pdf. Last accessed March 7, 2022. 66. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ . 2006;332(7553):1302-1308. 67. Ritenbaugh C, Stanford JL, Wu L, et al. Conjugated equine estrogens and colorectal cancer incidence and survival: the Women’s Health Initiative randomized clinical trial. Cancer Epidemiol Biomarkers Prev . 2008;17(10):2609-2618. 68. Simon MS, Chlebowski RT, Wactawski-Wende J, et al. Estrogen plus progestin and colorectal cancer incidence and mortality. J Clin Oncol . 2012;30(32):3983-3990. 69. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA . 2002;288(3):321-333. 70. Bostick RM, Potter JD, McKenzie DR, et al. Reduced risk of colon cancer with high intake of vitamin E: the Iowa Women’s Health Study. Cancer Res . 1993;53(18):4230-4237. 71. Lee IM, Cook NR, Gaziano JM, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women’s Health Study: a randomized controlled trial. JAMA . 2005;294(1):56-65. 72. Bjelakovic G, Nikolova D, Simonetti RG, Gluud C. Antioxidant supplements for prevention of gastrointestinal cancers: a systematic review and meta-analysis. Lancet . 2004;364(9441):1219-1228. 73. Gorham ED, Garland CF, Garland FC, et al. Vitamin D and prevention of colorectal cancer. J Steroid Biochem Mol Biol . 2005;97 (1- 2):179-194. 74. Pritchard RS, Baron JA, Gerhardsson de Verdier M. Dietary calcium, vitamin D, and the risk of colorectal cancer in Stockholm, Sweden. Cancer Epidemiol Biomarkers Prev . 1996;5(11):897-900. 75. Morales-Oyarvide V, Meyerhardt JA, Ng K. Vitamin D and physical activity in patients with colorectal cancer: epidemiological evidence and therapeutic implications. Cancer J . 2016;22(3):223-231. 76. Giovannucci E, Stampfer MJ, Colditz GA, et al. Multivitamin use, folate, and colon cancer in women in the Nurses’ Health Study. Ann Intern Med . 1998;129(7):517-524. 77. Eussen SJ, Vollset SE, Igland J, et al. Plasma folate, related genetic variants, and colorectal cancer risk in EPIC. Cancer Epidemiol Biomarkers Prev . 2010;19(5):1328-1340. 78. Cole BF, Baron JA, Sandler RS, et al. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA . 2007;297(21):2351-2359. 79. Baron JA, Beach M, Mandel JS, et al. Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group. N Engl J Med . 1999;340(2):101-107. 80. Grau MV, Baron JA, Sandler RS, et al. Prolonged effect of calcium supplementation on risk of colorectal adenomas in a randomized trial. J Natl Cancer Inst. 2007;99(2):129-136. 81. Wactawski-Wende J, Kotchen JM, Anderson GL, et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med . 2006;354(7):684-696. 82. Shaukat A, Scouras N, Schünemann HJ. Role of supplemental calcium in the recurrence of colorectal adenomas: a meta-analysis of randomized controlled trials. Am J Gastroenterol . 2005;100(2):390-394. 83. Bolland MJ, Avenell A, Baron JA, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta- analysis. BMJ . 2010;341:c3691. 84. Qaseem A, Denberg TD, Hopkins RH Jr. Screening for colorectal cancer: a guidance statement from the American College of Physicians. Ann Intern Med . 2012;156(5):378-386. 85. Mishra N, Hall J. Identification of patients at risk for hereditary colorectal cancer. Clin Colon Rectal Surg . 2012;25(2):67-82. 86. Imperiale TF, Juluri R, Sherer EA, Glowinski EA, Johnson CS, Morelli MS. A risk index for advanced neoplasia on the second surveillance colonoscopy in patients with previous adenomatous polyps. Gastrointest Endosc . 2014;80(3):471-478.
___________________________________________________________________________ Colorectal Cancer 87. American Society of Colon and Rectal Surgeons. Hereditary Colorectal Cancer. Available at https://fascrs.org/patients/diseases-and- conditions/a-z/hereditary-colorectal-cancer. Last accessed March 7, 2022. 88. Jasperson KW, Tuohy TM, Neklason DW, Burt RW. Hereditary and familial colon cancer. Gastroenterology . 2010;138(6):2044-2058. 89. National Cancer Institute. Genetics of Colorectal Cancer: Health Professional Version. Available at https://www.cancer.gov/types/ colorectal/hp/colorectal-genetics-pdq. Last accessed March 7, 2022. 90. Gala M, Chung DC. Hereditary colon cancer syndromes. Semin Oncol . 2011;38(4):490-499. 91. Pollock J, Welsh JS. Clinical cancer genetics: part I: gastrointestinal. Am J Clin Oncol . 2011;34(3):332-336. 92. Murff HJ, Peterson NB, Greevy R, Zheng W. Impact of patient age on family cancer history. Genet Med . 2006;8(7):438-442. 93. Chen S, Wang W, Lee S, et al. Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA . 2006;296(12):1479- 1487. 94. Lieberman DA, Rex DK, Winawer SJ, et al. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the U.S. Multi-Society Task Force on Colorectal Cancer. Gastroenterology . 2012;143(3):844-857. 95. Jang E, Chung DC. Hereditary colon cancer: Lynch syndrome. Gut Liver . 2010;4(2):151-160. 96. Patel SG, Ahnen DJ. Familial colon cancer syndromes: an update of a rapidly evolving field. Curr Gastroenterol Rep . 2012;14(5):428-438. 97. Giardiello FM, Allen JI, Axilbund JE, et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the U.S. Multi-Society Task Force on colorectal cancer. Gastroenterology . 2014;147(2):502-526. 98. Khan O, Blanco A, Conrad P, et al. Performance of Lynch syndrome predictive models in a multi-center U.S. referral population. Am J Gastroenterol . 2011;106(10):1822-1827. 99. Jasperson KW, Vu TM, Schwab AL, et al. Evaluating Lynch syndrome in very early onset colorectal cancer probands without apparent polyposis. Fam Cancer. 2010;9(2):99-107. 100. Boland CR. Evolution of the nomenclature for the hereditary colorectal cancer syndromes. Fam Cancer . 2005;4(3):211-218. 101. Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology . 1999;116(6):1453-1456. 102. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst . 2004;96(4):261-268. 103. Kastrinos F, Syngal S. Inherited colorectal cancer syndromes. Cancer J . 2011;17(6):405-415. 104. Vasen HF, Blanco I, Aktan-Collan K, et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut . 2013;62(6):812-823. 105. Parry S, Win AK, Parry B, et al. Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery. Gut . 2011;60(7):950-957. 106. Vasen HF, Möslein G, Alonso A, et al. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet . 2007;44(6):353-362. 107. Renkonen-Sinisalo L, Seppälä TT, Järvinen HJ, Mecklin JP. Subtotal colectomy for colon cancer reduces the need for subsequent surgery in Lynch syndrome. Dis Colon Rectum . 2017;60(8):792-799. 108. Kim TJ, Kim ER, Hong SN, et al. Survival outcome and risk of metachronous colorectal cancer after surgery in Lynch syndrome. Ann Surg Oncol . 2017;24(4):1085-1092. 109. Rodriguez-Bigas MA, Möeslein G. Surgical treatment of hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome). Fam Cancer . 2013;12(2):295-300. 110. Laken SJ, Petersen GM, Gruber SB, et al. Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nat Genet . 1997;17(1):79-83. 111. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Genetic/Familial High-Risk Assessment: Colorectal. Available at https://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf. Last accessed March 7, 2022. 112. Vasen HF, Möslein G, Alonso A, et al. Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut . 2008;57(5):704-713. 113. Iwama T, Tamura K, Morita T, et al. A clinical overview of familial adenomatous polyposis derived from the database of the Polyposis Registry of Japan. Int J Clin Oncol . 2004;9(4):308-316. 114. Libutti SK, Willett CG, Saltz LB, Levine RA. Cancer of the rectum. In: DeVita VT Jr, Lawrence TS, Rosenberg SA (eds). Cancer: Principles and Practice of Oncology . 11th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2018: 970-996. 115. Shaukat A, Kahi CJ, Burke CA, Rabeneck L, Sauer BG, Rex DK. ACG clinical guidelines: colorectal cancer screening 2021. Am J Gastroenterol . 2021;116(3):458-479. 116. Hampel H. Genetic testing for hereditary colorectal cancer. Surg Oncol Clin N Am . 2009;18(4):687-703. 117. Burt R, Neklason DW. Genetic testing for inherited colon cancer. Gastroenterology . 2005;128(6):1696-1716. 118. Farraye FA, Odze RD, Eaden J, Itzkowitz SH. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology . 2010;138(2):746-774.
Colorectal Cancer _ ___________________________________________________________________________ 119. Nishihara R, Wu K, Lochhead P, et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. New Engl J Med . 2013;369(12):1095-1105. 120. Stracci F, Zorzi M, Grazzini G. Colorectal cancer screening: tests, strategies, and perspectives. Front Public Health . 2014;2:210. 121. U.S. Preventive Services Task Force. Colorectal Cancer: Screening. Available at https://www.uspreventiveservicestaskforce.org/uspstf/ recommendation/colorectal-cancer-screening. Last accessed March 7, 2022. 122. Zauber AG, Winawer SJ, O’Brien MJ, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med . 2012;366(8):687-696. 123. Shaukat A, Mongin SJ, Geisser MS, et al. Long-term mortality after screening for colorectal cancer. N Engl J Med . 2013;369(12):1106- 1114. 124. Brenner H, Chang-Claude J, Jansen L, Knebel P, Stock C, Hoffmeister M. Reduced risk of colorectal cancer up to 10 years after screening, surveillance, or diagnostic colonoscopy. Gastroenterology . 2014;146(3):709-717. 125. Løberg M, Kalager M, Holme Ø, Hoff G, Adami HO, Bretthauer M. Long-term colorectal-cancer mortality after adenoma removal. N Engl J Med . 2014;371(9):799-807. 126. Klabunde CN, Cronin KA, Breen N, et al. Trends in colorectal cancer test use among vulnerable populations in the United States. Cancer Epidemiol Biomarkers Prev . 2011;20(8):1611-1621. 127. American Cancer Society. Colorectal Cancer Stages. Available at https://www.cancer.org/cancer/colon-rectal-cancer/detection- diagnosis-staging/staged.html. Last accessed March 7, 2022. 128. Oxentenko AS, Goel NK, Pardi DS, et al. Colorectal cancer screening education, prioritization, and self-perceived preparedness among primary care residents: data from a national survey. J Cancer Educ . 2007;22(4):208-218. 129. Hampel H. NCCN increases the emphasis on genetic/familial high-risk assessment in colorectal cancer. J Natl Compr Canc Netw . 2014;12(5 Suppl):829-831. 130. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Colorectal Cancer Screening. Available at https://www.nccn.org/professionals/physician_gls/pdf/colorectal_screening.pdf. Last accessed March 7, 2022. 131. Mayo Clinic. Colonoscopy. Available at https://www.mayoclinic.org/tests-procedures/colonoscopy/about/pac-20393569#. Last accessed March 7, 2022. 132. Bressler B, Paszat LF, Chen Z, Rothwell DM, Vinden C, Rabeneck L. Rates of new or missed colorectal cancers after colonoscopy and their risk factors: a population-based analysis. Gastroenterology . 2007;132(1):96-102. 133. Warren JL, Klabunde CN, Mariotto AB, et al. Adverse events after outpatient colonoscopy in the Medicare population. Ann Intern Med . 2009;150(12):849-857. 134. ASGE Standards of Practice Committee, Fisher DA, Maple JT, et al. Complications of colonoscopy. Gastrointestinal Endosc . 2011;74(4):745-753. 135. Rabeneck L, Paszat LF, Hilsden RJ, et al. Bleeding and perforation after outpatient colonoscopy and their risk factors in usual clinical practice. Gastroenterology . 2008;135(6):1899-1906. 136. Levin TR, Zhao W, Conell C, et al. Complications of colonoscopy in an integrated health care delivery system. Ann Intern Med . 2006;145(12):880-886. 137. Johnson DA, Barkun AN, Cohen LB, et al. Optimizing adequacy of bowel cleansing for colonoscopy: recommendations from the U.S. Multi-Society Task Force on Colorectal Cancer. Gastroenterology . 2014;147(4):903-924. 138. Froehlich F, Wietlisbach V, Gonvers JJ, Burnand B, Vader JP. Impact of colonic cleansing on quality and diagnostic yield of colonoscopy: the European Panel of Appropriateness of Gastrointestinal Endoscopy European multicenter study. Gastrointest Endosc . 2005;61(3):378-384. 139. Harewood GC, Sharma VK, de Garmo P. Impact of colonoscopy preparation quality on detection of suspected colonic neoplasia. Gastrointest Endosc . 2003;58(1):76-79. 140. Rex DK, Imperiale TF, Latinovich DR, Bratcher LL. Impact of bowel preparation on efficiency and cost of colonoscopy. Am J Gastroenterol . 2002;97(7):1696-1700. 141. Peery AF, Crockett SD, Murphy CC, et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2018. Gastroenterology . 2019;156(1):254-272. 142. Rex DK, Schoenfeld PS, Cohen J, et al. Quality indicators for colonoscopy. Am J Gastroenterol . 2015;110(1):72-90. 143. Baxter N, Sutradhar R, Forbes SS, Paszat LF, Saskin R, Rabeneck L. Analysis of administrative data finds endoscopist quality measures associated with post-colonoscopy colorectal cancer. Gastroenterology . 2011;140(1):65-72. 144. Shaukat A, Oancea C, Bond JH, Church TR, Allen JI. Variation in detection of adenomas and polyps by colonoscopy and change over time with a performance improvement program. Clin Gastroenterol Hepatol . 2009;7(12):1335-1340. 145. Imperiale TF, Glowinski EA, Juliar BE, Azzouz F, Ransohoff DF. Variation in polyp detection rates at screening colonoscopy. Gastrointest Endosc . 2009;69(7):1288-1295. 146. Pohl H, Robertson DJ. Colorectal cancers detected after colonoscopy frequently result from missed lesions. Clin Gastroenterol Hepatol . 2010;8(10):858-864.
___________________________________________________________________________ Colorectal Cancer 147. Simmons DT, Harewood GC, Baron TH, et al. Impact of endoscopist withdrawal speed on polyp yield: implications for optimal colonoscopy withdrawal time. Aliment Pharmacol Ther . 2006;24(6):965-971. 148. Lim G, Viney SK, Chapman BA, Frizelle FA, Gearry RB. A prospective study of endoscopist-blinded colonoscopy withdrawal times and polyp detection rates in a tertiary hospital. N Z Med J. 2012;125(1356):52-59. 149. Barclay RL, Vicari JJ, Doughty AS, Johanson JF, Greenlaw RL. Colonoscopic withdrawal times and adenoma detection during screening colonoscopy. N Engl J Med . 2006;355(24):2533-2541. 150. National Institute of Diabetes and Digestive and Kidney Diseases. Virtual Colonoscopy. Available at https://www.niddk.nih.gov/ health-information/diagnostic-tests/virtual-colonoscopy. Last accessed March 7, 2022. 151. You JJ, Liu Y, Kirby J, Vora P, Moayyedi P. virtual colonoscopy, optical colonoscopy, or fecal occult blood testing for colorectal cancer screening: results of a pilot randomized controlled trial. Trials . 2015;16:296. 152. Zalis ME, Blake MA, Cai W, et al. Diagnostic accuracy of laxative-free computed tomographic colonography for detection of adenomatous polyps in asymptomatic adults: a prospective evaluation. Ann Intern Med . 2012;156(10):692-702. 153. Kimberly JR, Phillips KC, Santago P, et al. Extracolonic findings at virtual colonoscopy: an important consideration in asymptomatic colorectal cancer screening. J Gen Intern Med . 2009;24(1):69-73. 154. Pickhardt PJ, Hanson ME, Vanness DJ, et al. Unsuspected extracolonic findings at screening CT colonography: clinical and economic impact. Radiology . 2008;249(1):151-159. 155. Maggialetti N, Capasso R, Pinto D, et al. Diagnostic value of computed tomography colonography (CTC) after incomplete optical colonoscopy. Int J Surg . 2016;(33 Suppl 1):S36-S44. 156. National Institute of Diabetes and Digestive and Kidney Diseases. Flexible Sigmoidoscopy. Available at https://www.niddk.nih.gov/ health-information/diagnostic-tests/flexible-sigmoidoscopy. Last accessed March 7, 2022. 157. Levin TR, Palitz A, Grossman S, et al. Predicting advanced proximal colonic neoplasia with screening sigmoidoscopy. JAMA . 1999;281(17):1611-1617. 158. National Cancer Institute. Double-Contrast Barium Enema. Available at https://www.cancer.gov/publications/dictionaries/cancer- terms/def/double-contrast-barium-enema. Last accessed March 7, 2022. 159. National Colorectal Cancer Roundtable. Clinician’s Reference: Fecal Occult Blood Testing (FOBT) for Colorectal Cancer Screening. Available at http://nccrt.org/wp-content/uploads/FOBTCliniciansReferenceFinal.pdf. Last accessed March 7, 2022. 160. Levi Z, Rozen P, Hazazi R, et al. A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med . 2007;146(4):244-255. 161. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med . 2014;370:1287-1297. 162. Hewitson P, Glasziou P, Irwig L, Towler B, Watson E. Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database Syst Rev . 2007;24(1):CD001216. 163. Qaseem A, Crandell CJ, Mustafa RA, Hicks LA, Wilt TJ. Screening for colorectal cancer in asymptomatic average-risk adults: a guidance statement from the American College of Physicians. Ann Intern Med . 2019;171(9):643-654. 164. Gupta S, Lieberman D, Anderson JC, et al. Recommendations for follow-up after colonoscopy and polypectomy: a consensus update by the U.S. Multi-society Task Force on Colorectal Cancer. Gastrointestinal Endosc . 2020;91(3):463-485. 165. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the U.S. Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin . 2008;58(3):130-160. 166. Cairns SR, Scholefield JH, Steele RJ, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut . 2010;59(5):666-690. 167. Singh H, Turner D, Xue L, Targownik LE, Bernstein CN. Risk of developing colorectal cancer following a negative colonoscopy examination. JAMA . 2006;295(20):2366-2373. 168. Robertson DJ, Lieberman DA, Winawer SJ, et al. Interval cancer after total colonoscopy: results from a pooled analysis of eight studies. Gastroenterology . 2008;134(4 Suppl 1):A111-A112. 169. Grady WM, Pritchard CC. Molecular alterations and biomarkers in colorectal cancer. Toxicol Pathol . 2014;42(1):124-139. 170. Al-Sohaily S, Biankin A, Leong R, Kohonen-Corish M, Warusavitarne J. Molecular pathways in colorectal cancer. J Gastroenterol Hepatol . 2012;27(9):1423-1431. 171. BMJ Best Practice. Colorectal Cancer. Available at https://bestpractice.bmj.com/topics/en-us/258. Last accessed March 7, 2022. 172. National Cancer Institute: Surveillance, Epidemiology, and End Results Program. SEER Cancer Statistics Review 1975-2018. Available at https://seer.cancer.gov/csr/1975_2018. Last accessed March 7, 2022. 173. Saclarides TJ, Szeluga D, Staren ED. Neuroendocrine cancers of the colon and rectum: results of a ten-year experience. Dis Colon Rectum . 1994;37(7):635-642. 174. Johns LE, Houlston RS. A systematic review and meta-analysis of familial colorectal cancer risk. Am J Gastroenterol . 2001;96(10):2992- 3003.
Colorectal Cancer _ ___________________________________________________________________________ 175. Burt RW. Familial risk and colorectal cancer. Gastroenterol Clin North Am . 1996;25(4):793-803. 176. Kang H, O’Connell JB, Leonardi MJ, Maggard MA, Mcgory ML, Ko CY. Rare tumors of the colon and rectum: a national review. Int J Colorectal Dis . 2007;22(2):183-189. 177. Arnold CN, Goel A, Blum HE, Boland CR. Molecular pathogenesis of colorectal cancer. Cancer . 2005;104(10):2035-2047. 178. Wu K, Keum N, Nishihara R, Giovannucci EL. Cancers of the colon and rectum. In: Thun MJ, Linet MS, Cerhan JR, Haiman CA, Schottenfeld D (eds). Cancer Epidemiology and Prevention . 4th ed. New York, NY: Oxford University Press; 2018: 681-706. 179. Manne U, Shanmugam C, Katkoori VR, Bumpers HL, Grizzle WE. Development and progression of colorectal neoplasia. Cancer Biomark . 2010;9(1-6):235-265. 180. Shah NB, Lindor NM. Lower gastrointestinal tract cancer predisposition syndromes. Hematol Oncol Clin North Am . 2010;24(6):1229- 1252. 181. Pritchard CC, Grady WM. Colorectal cancer molecular biology moves into clinical practice. Gut . 2011;60(1):116-129. 182. De Jong AE, Morreau H, Van Puijenbroek M, et al. The role of mismatch repair gene defects in the development of adenomas in patients with HNPCC. Gastroenterology . 2004;126(1):42-48. 183. Grizzle WE, Srivastava S, Manne U. The biology of incipient, pre-invasive or intraepithelial neoplasia. Cancer Biomark . 2011;9 (1-6):21- 39. 184. Reeves HL, Narla G, Ogunbiyi O, et al. Kruppel-like factor 6 (KLF6) is a tumor-suppressor gene frequently inactivated in colorectal cancer. Gastroenterology . 2004;126(4):1090-1103. 185. Gonsalves WI, Mahoney MR, Sargent DJ, et al. Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance No. 147. J Natl Cancer Inst . 2014;106(7):dju106. 186. Sideris M, Papagrigoriadis S. Molecular biomarkers and classification models in the evaluation of the prognosis of colorectal cancer. Anticancer Res . 2014;34(5):2061-2068. 187. Monson JRT, Weiser MR, Buie WD, et al. Practice parameters for the management of rectal cancer (revised). Dis Colon Rectum . 2013;56(5):535-550. 188. Chang GJ, Kaiser AM, Mills S, et al. Practice parameters for the management of colon cancer. Dis Colon Rectum . 2012;55:831-843. 189. Butterworth AS, Higgins JP, Pharoah P. Relative and absolute risk of colorectal cancer for individuals with a family history: a meta- analysis. Eur J Cancer. 2006;42(2):216-227. 190. Kanellos D, Kitsios G, Kanellos I, et al. Anemia as a symptom of right colon cancer. Tech Coloproctol . 2004;8(Suppl 1):S62-S64. 191. du Toit J, Hamilton W, Barraclough K. Risk in primary care of colorectal cancer from new onset rectal bleeding: 10 year prospective study. BMJ . 2006;333(7558):69-70. 192. Fisher SE, Daniels LR. The clinical presentation of colorectal cancer. In: Brown G (ed). Colorectal Cancer: Contemporary Issues in Cancer Imaging . Cambridge: Cambridge University Press; 2008: 1-14. 193. Halligan S, Wooldrage K, Dadswell E, et al. Computed tomographic colonography versus barium enema for diagnosis of colorectal cancer or large polyps in symptomatic patients (SIGGAR): a multicentre randomised trial. Lancet . 2013;381(9873):1185-1193. 194. Atkin W, Dadswell E, Wooldrage K, et al. Computed tomographic colonography versus colonoscopy for investigation of patients with symptoms suggestive of colorectal cancer (SIGGAR): a multicentre randomised trial. Lancet . 2013;381(9873):1194-1202. 195. ASGE Standards of Practice Committee, Fisher DA, Shergill AK, et al. Role of endoscopy in the staging and management of colorectal cancer. Gastrointest Endosc . 2013;78(1):8-12. 196. Ganeshan A, Upponi S, Uberoi R, D’Costa H, Picking C, Bungay H. Minimal-preparation CT colon in detection of colonic cancer, the Oxford experience. Age Ageing . 2007;36(1):48-52. 197. Kealey SM, Dodd JD, MacEneaney PM, Gibney RG, Malone DE. Minimal preparation computed tomography instead of barium enema/colonoscopy for suspected colon cancer in frail elderly patients: an outcome analysis study. Clin Radiol . 2004;59(1):44-52. 198. Al-Sukhni E, Milot L, Fruitman M, et al. Diagnostic accuracy of MRI for assessment of T category, lymph node metastases, and circumferential resection margin involvement in patients with rectal cancer: a systematic review and meta-analysis. Ann Surg Oncol . 2012;19(7):2212-2223. 199. Zhang C, Chen Y, Xue H, et al. Diagnostic value of FDG-PET in recurrent colorectal carcinoma: a meta-analysis. Int J Cancer . 2009;124(1):167-173. 200. Kennedy E, Vella E, MacDonald DB, Wong CS, McLeod R. Optimization of preoperative assessment in patients diagnosed with rectal cancer. Clin Oncol (R Coll Radiol) . 2015;27(4):225-245. 201. National Cancer Institute. Colon Cancer Treatment: Health Professional Version. Available at https://www.cancer.gov/types/ colorectal/hp/colon-treatment-pdq. Last accessed March 7, 2022. 202. Amin MB, Edge SB, Greene F, et al. (eds). AJCC Cancer Staging Manual . 8th ed. New York, NY: Springer; 2018. 203. American Joint Committee on Cancer. Cancer Staging System. Available at https://www.facs.org/quality-programs/cancer/ajcc/ cancer-staging.What-is-Cancer-Staging.aspx. Last accessed March 7, 2022.
___________________________________________________________________________ Colorectal Cancer 204. American Cancer Society. Colorectal Cancer Stages. Available at https://www.cancer.org/cancer/colon-rectal-cancer/detection- diagnosis-staging/staged.html. Last accessed March 7, 2022. 205. National Cancer Institute. Rectal Cancer Treatment: Health Professional Version. Available at https://www.cancer.gov/types/ colorectal/hp/rectal-treatment-pdq. Last accessed March 7, 2022. 206. Jimeno A, Messersmith WA, Hirsch FR, Franklin WA, Eckhardt SG. KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J Clin Oncol . 2009;27(7):1130-1136. 207. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med . 2003;349(3):247-257. 208. Quasar Collaborative Group, Gray R, Barnwell J. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet . 2007;370(9604):2020-2029. 209. Kawakami H, Zaanan A, Sinicrope FA. MSI testing and its role in the management of colorectal cancer. Curr Treat Options Oncol . 2015;16(7):30. 210. Mlecnik B, Tosolini M, Kirilovsky A, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol . 2011;29(6):610-618. 211. Ogino S, Kawasaki T, Kirkner GJ, Ohnishi M, Fuchs CS. 18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) and inversely with CIMP-low and CIMP-high. BMC Cancer . 2007;7:72. 212. Hugen N, van de Velde CJ, de Wilt JH, Nagtegaal ID. Metastatic pattern in colorectal cancer is strongly influenced by histological subtype. Ann Oncol . 2014;25(3):651-657. 213. Chua TC, Saxena A, Chu F, Zhao J, Morris DL. Predictors of cure after hepatic resection of colorectal liver metastases: an analysis of actual 5- and 10-year survivors. J Surg Oncol . 2011;103(8):796-800. 214. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg . 1999;230(3):309-318. 215. Aggarwal C, Meropo NJ, Punt CJ, et al. Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer. Ann Oncol . 2013;24(2):420-428. 216. Donadon M, Lleo A, Di Tommaso L, et al. The shifting paradigm of prognostic factors of colorectal liver metastases: from tumor- center to host immune-centered factors. Front Oncol . 2018;8:181. 217. Van der Jeught K, Xu HC, Li YJ, Lu XB, Ji G. Drug resistance and new therapies in colorectal cancer. World J Gastroenterol . 2018;24(34):3834-3848. 218. Angiogenesis Foundation. Update on Antiangiogenic Therapy for Metastatic Colorectal Cancer. Available at http://www.angio.org/ pdf/CRC2013ePub.pdf. Last accessed March 7, 2022. 219. Gezen C, Kement M, Altuntas YE, et al. Results after multivisceral resections of locally advanced colorectal cancers: an analysis on clinical and pathological t4 tumors. World J Surg Oncol . 2012;10:39. 220. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Colon Cancer. Available at https://www.nccn. org/professionals/physician_gls/pdf/colon.pdf. Last accessed March 7, 2022. 221. National Cancer Institute. Drugs Approved for Colon and Rectal Cancer. Available at https://www.cancer.gov/about-cancer/ treatment/drugs/colorectal. Last accessed March 7, 2022. 222. Lexicomp Online. Available at https://online.lexi.com/lco/action/login. Last accessed March 7, 2022. 223. The Angiogenesis Foundation. Treatments: Angiogenesis Inhibitors for Cancer. Available at https://angio.org/learn/treatments. Last accessed March 7, 2022. 224. U.S. Food and Drug Administration. FDA Approves First-Line Immunotherapy for Patients with MSI-H/dMMR Metastatic Colorectal Cancer. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-first-line-immunotherapy-patients-msi- hdmmr-metastatic-colorectal-cancer. Last accessed March 7, 2022. 225. Woo J, Palmisiano N, Tester W, Leighton JC Jr. Controversies in antiepidermal growth factor receptor therapy in metastatic colorectal cancer. Cancer . 2013;119(11):1941-1950. 226. Knijn N, Tol J, Punt CJ. Current issues in the targeted therapy of advanced colorectal cancer. Discov Med . 2010;9(47):328-336. 227. Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature . 2012;486(7404):532-536. 228. Kim TW, Elme A, Kusic Z, et al. A phase 3 trial evaluating panitumumab plus best supportive care vs. best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer. Br J Cancer . 2016;115(10):1206-1214. 229. Peeters M, Oliner KS, Price TJ, et al. Analysis of KRAS/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer. Clin Cancer Res . 2015;21(24):5469-5479. 230. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Rectal Cancer. Available at https://www.nccn. org/professionals/physician_gls/pdf/rectal.pdf. Last accessed March 7, 2022.
Colorectal Cancer _ ___________________________________________________________________________ 231. Hines RB, Barrett A, Twumasi-Ankrah P, et al. Predictors of guideline treatment nonadherence and the impact on survival in patients with colorectal cancer. J Natl Compr Canc Netw . 2015;13(1):51-60. 232. Panettiere FJ, Goodman PJ, Costanzi JJ, et al. Adjuvant therapy in large bowel adenocarcinoma: long-term results of a Southwest Oncology Group study. J Clin Oncol . 1988;6(6):947-954. 233. Franklin ME Jr, Rosenthal D, Abrego-Medina D, et al. Prospective comparison of open vs. laparoscopic colon surgery for carcinoma: five-year results. Dis Colon Rectum . 1996;39(10 Suppl):S35-S46. 234. Weeks JC, Nelson H, Gelber S, et al. Short-term quality-of-life outcomes following laparoscopic-assisted colectomy vs. open colectomy for colon cancer: a randomized trial. JAMA . 2002;287(3):321-328. 235. Jayarajah U, Samarasekera AM, Samarasekera DN. A study of postoperative anxiety and depression among patients with intestinal stomas. Sri Lanka J Surg . 2016;34(2):6-10. 236. Liao C, Qin Y. Factors associated with stoma quality of life among stoma patients. Int J Nurs Sci . 2014;1(2):196-201. 237. Farrell M. Smeltzer and Bares Textbook of Medical-Surgical Nursing . 4th ed. Netherlands: Wolters Kluwer Health; 2016. 238. National Institute for Health and Clinical Excellence. Colorectal Cancer. Available at https://www.nice.org.uk/guidance/ng151. Last accessed March 7, 2022. 239. Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol . 2004;22(10):1797-1806. 240. Benson AB III, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol . 2004;22(16):3408-3419. 241. André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol . 2009;27(19):3109-3116. 242. Fujita K, Kubota Y, Ishida H, Sasaki Y. Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer. World J Gastroenterol . 2015;21(43):12234-12248. 243. Martin LK, Bekaii-Saab T. Optimizing neoadjuvant therapy for rectal cancer with oxaliplatin. J Natl Compr Canc Netw . 2013;11(3):298- 307. 244. Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol . 2012;30(16):1926- 1933. 245. Roh MS, Colangelo LH, O’Connell MJ, et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol . 2009;27(31):5124-5130. 246. Willett CG, Badizadegan K, Ancukiewicz M, Shellito PC. Prognostic factors in stage T3N0 rectal cancer: do all patients require postoperative pelvic irradiation and chemotherapy? Dis Colon Rectum . 1999;42(2):167-173. 247. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med . 2004;351(17):1731-1740. 248. Seitz U, Bohnacker S, Seewald S, et al. Is endoscopic polypectomy an adequate therapy for malignant colorectal adenomas? Presentation of 114 patients and review of the literature. Dis Colon Rectum . 2004;47(11):1789-1796. 249. Peng J, Chen W, Venook AP, et al. Long-term outcome of early-stage rectal cancer undergoing standard resection and local excision. Clin Colorectal Cancer . 2011;10(1):37-41. 250. Stitzenberg KB, Sanoff HK, Penn DC, Meyers MO, Tepper JF. Practice patterns and long-term survival for early-stage rectal cancer. J Clin Oncol . 2013;31(34):4276-4282. 251. Nash GM, Weiser MR, Guillem JG, et al. Long-term survival after transanal excision of T1 rectal cancer. Dis Colon Rectum . 2009;52(4):577-582. 252. Brown CJ, Fenech DS, McLeod RS. Reconstructive techniques after rectal resection for rectal cancer. Cochrane Database Syst Rev . 2008;(2):CD006040. 253. Maurer CA, Renzulli P, Kull C, et al. The impact of the introduction of total mesorectal excision on local recurrence rate and survival in rectal cancer: long-term results. Ann Surg Oncol . 2011;18(7):1899-1906. 254. Baxter NN, Garcia-Aguilar J. Organ preservation for rectal cancer. J Clin Oncol . 2007;25(8):1014-1020. 255. Fujita S, Akasu T, Mizusawa J, et al. Postoperative morbidity and mortality after mesorectal excision with and without lateral lymph node dissection for clinical stage II or stage III lower rectal cancer (JCOG0212): results from a multicentre, randomised controlled, noninferiority trial. Lancet Oncol . 2012;13(6):616-621. 256. Knol J, Keller DS. Total mesorectal excision technique – past, present, and future. Clin Colon Rectal Surg . 2020;33(3):134-143. 257. Cagir B. Rectal Cancer Treatment and Management. Available at https://emedicine.medscape.com/article/281237-treatment. Last accessed March 7, 2022. 258. Wong R, Berry S, Spithoff K, et al. Preoperative or Postoperative Therapy for the Management of Patients with Stage II or III Rectal Cancer. Available at https://www.cancercareontario.ca/en/guidelines-advice/types-of-cancer/31891. Last accessed March 7, 2022.
___________________________________________________________________________ Colorectal Cancer 259. Sebag-Montefiore D, Stephens RJ, Steele R, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet . 2009;373(9666):811-820. 260. Valentini V, Beets-Tan R, Borras JM, et al. Evidence and research in rectal cancer. Radiother Oncol . 2008;87(3):449-474. 261. Abraha I, Aristei C, Palumbo I, et al. Pre-operative radiotherapy and curative surgery for the management of localized rectal carcinoma. Cochrane Database Syst Rev . 2018;(10):CD002102. 262. Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med . 2006;355(11):1114- 1123. 263. Weiser MR, Quah HM, Shia J, et al. Sphincter preservation in low rectal cancer is facilitated by preoperative chemoradiation and intersphincteric dissection. Ann Surg . 2009;249(2):236-242. 264. De Caluwé L, Van Nieuwenhove Y, Ceelen WP. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. Cochrane Database Syst Rev . 2013;2:CD006041. 265. Jakobsen A, Ploen J, Vuong T, Appelt A, Lindebjerg J, Rafaelsen SR. Dose-effect relationship in chemoradiotherapy for locally advanced rectal cancer: a randomized trial comparing two radiation doses. Int J Radiat Oncol Biol Phys . 2012;84(4):949-954. 266. Benson AB III, Venook AP, Bekaii-Saab T, et al. Colon cancer, version 3.2014. J Natl Compr Canc Netw . 2014;12(7):1028-1059. 267. National Cancer Institute. NCI Dictionary of Cancer Terms. Available at https://www.cancer.gov/publications/dictionaries/ cancer- terms. Last accessed March 7, 2022. 268. Dragovich T, Tsikitis VL. Colon Cancer Medication. Available at https://emedicine.medscape.com/article/277496-medication. Last accessed March 7, 2022. 269. Cagir B, Trostle DR. Rectal Cancer Medication. Available at https://emedicine.medscape.com/article/281237-medication. Last accessed March 7, 2022. 270. Wang JH, King TM, Chang MC, Hsu CW. Oxaliplatin-induced severe anaphylactic reactions in metastatic colorectal cancer: case series analysis. World J Gastroenterol . 2012;18(38):5427-5433. 271. Saif MW, Relias V, Syrigos K, Gunturu KS. Incidence and management of ziv-aflibercept related toxicities in colorectal cancer. World J Clin Oncol . 2014;5(5):1028-1035. 272. Matin K. Colon Cancer Treatment Protocols. Available at https://emedicine.medscape.com/article/2005487-overview. Last accessed March 7, 2022. 273. Poston GJ, Adam R, Alberts S, et al. OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol . 2005;23(28):7125-7134. 274. Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg . 2002;235(6):759-766. 275. Rodriguez-Bigas MA, Herrera L, Petrelli NJ. Surgery for recurrent rectal adenocarcinoma in the presence of hydronephrosis. Am J Surg . 1992;164(1):18-21. 276. Vermaas M, Ferenschild FT, Verhoef C, et al. Total pelvic exenteration for primary locally advanced and locally recurrent rectal cancer. Eur J Surg Oncol . 2007;33(4):452-458. 277. Ogunbiyi OA, McKenna K, Birnbaum EH, Fleshman JW, Kodner IJ. Aggressive surgical management of recurrent rectal cancer—is it worthwhile? Dis Colon Rectum . 1997;40(2):150-155. 278. Weiser MR, Landmann RG, Wong WD, et al. Surgical salvage of recurrent rectal cancer after transanal excision. Dis Colon Rectum . 2005;48(6):1169-1175. 279. Ducreux M, Malka D, Mendiboure J, et al. Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial. Lancet Oncol . 2011;12(11):1032-1044. 280. Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ . 1993;306(6880):752-755. 281. Leichman CG, Fleming TR, Muggia FM, et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol . 1995;13(6):1303-1311. 282. Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G, Piedbois P. Relation between tumour response to first- line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. Lancet . 2000;356(9227):373-378. 283. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol . 2001;19(21):4097-4106. 284. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol . 2001;19(8):2282- 2292. 285. Díaz-Rubio E, Tabernero J, Gómez-España A, et al. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol . 2007;25(27):4224-4230.
Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 Page 10 Page 11 Page 12 Page 13Powered by FlippingBook